Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Recover your password.
A password will be e-mailed to you.
Access to up to $400 million expected to provide cash runway through at least 2025
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended September 30, 2022, and provides a corporate update.
“We have significantly strengthened our financial position with access up to approximately $400 million, through our cash on hand and recently announced $150 million debt facility from Oxford Finance,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “We expect these funds to extend our cash runway through at least the end of 2025, supporting the ongoing pre-commercialization activities for ensifentrine and the planned commercial launch in the United States.
“Ensifentrine demonstrated consistent positive effects across primary and secondary endpoints of lung function including subgroups in the Phase 3 ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial. Additional analyses demonstrated positive effects of ensifentrine in reducing rates of exacerbations across clinically relevant subgroups. We are very encouraged by these data and look forward to reporting our ENHANCE-1 results around the end of the year.
“Alongside our clinical progress, Nuance Pharma, our development partner, received clearance from China’s Center for Drug Evaluation (“CDE”) to begin Phase 1 and Phase 3 studies with ensifentrine for chronic obstructive pulmonary disease (“COPD”) in mainland China. Nuance Pharma is responsible for developing and commercializing ensifentrine in Greater China and we look forward to providing future updates.”
Program Updates and Key Milestones
The Company’s near-term milestones include:
Third Quarter and Recent Highlights
Third Quarter 2022 Financial Results
Conference Call and Webcast Information
Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Wednesday, November 9, 2022, to discuss the third quarter financial results and the corporate update.
To participate, please dial one of the following numbers and ask to be placed into the Verona Pharma third quarter earnings call:
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the third quarter 2022 results press release will also be made available today on the Company’s website.
For further information please contact:
|Verona Pharma plc||US Tel: +1-833-417-0262
UK Tel: +44 (0)203 283 4200
|Victoria Stewart, Director of Investor Relations and Communications||IR@veronapharma.com|
(US Investor Enquiries)
|Kimberly Minarovich / Carrie McKim|
|Optimum Strategic Communications
(International Media and European Investor Enquiries)
|Tel: +44 (0)203 882 9621
|Mary Clark / Rebecca Noonan / Zoe Bolt|
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial. ENHANCE-1 is expected to report around the end of 2022. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our operational review, outlook and financial review, the development of ensifentrine and the progress and timing of clinical trials and data, the assumptions underlying the Company’s models on clinical trial progress, the timing of submission of an NDA for ensifentrine, the potential for ensifentrine to be the first therapy for the treatment of respiratory diseases to combine bronchodilator and anti-inflammatory effects in one compound, the potential of ensifentrine in the treatment of COPD, cystic fibrosis, asthma and other respiratory diseases, as well as the potential of the DPI and pMDI formulations of ensifentrine, the funding we expect to become available under the $150.0 million debt financing facility and from cash receipts from UK tax credits, and the sufficiency of cash and cash equivalents, and the cash runway period provided by the sources of financing through to at least the end of 2025 and the fully funding of the commercial launch.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine; potential delays in enrolling subjects, which could adversely affect our research and development efforts and the completion of our clinical trials; we may not be successful in developing ensifentrine for multiple indications; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, third-party service providers and licensees; our inability to realize the anticipated benefits under licenses granted by us to third parties to develop and commercialize ensifentrine, our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel; material differences between our “top-line” data and final data; our reliance on third parties, including clinical research organizations, clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable; lawsuits related to our licensing of patents and know-how with third parties for the development and commercialization of ensifentrine; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods; and our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics like the COVID-19 pandemic, and conflicts such as the Russia-Ukraine conflict, which has and may continue to adversely impact our business. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Verona Pharma plc
Consolidated Financial Summary
|Three months ended September 30,|
|Research and development||$||9,838||$||22,560|
|Selling, general and administrative||5,290||10,883|
|Total operating expenses||15,128||33,443|
|Research and development tax credit||2,127||4,749|
|Fair value movement on warrants||–||40|
|Foreign exchange loss||(3,245||)||(86||)|
|Total other (expense)/income, net||(455||)||4,621|
|(Loss)/profit before income taxes||(15,583||)||11,178|
|Income tax expense||(64||)||(127||)|
|Weighted-average shares outstanding – basic||544,134,136||475,334,354|
|Weighted-average shares outstanding – diluted||544,134,136||515,819,439|
|(Loss)/profit per ordinary share – basic||$||(0.03||)||$||0.02|
|(Loss)/profit per ordinary share – diluted||(0.03||)||0.02|
|Cash and cash equivalents||$||231,701||$||111,510|
Get real time updates directly on you device, subscribe now.